A Phase 3 interventional study of Lenalidomide and Dexamethasone in Newly Diagnosed, Previously Untreated Multiple Myeloma, sponsored by Bristol-Myers Squibb. Terminated at 14 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-01.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 249 studies testing lenalidomide in Multiple Myeloma — 29 open to participants now, 70 under way, 14 of them phase 3. Lenalidomide · Multiple Myeloma.
Among the 249 studies testing lenalidomide in Multiple Myeloma, this one is the 184th largest by enrollment, is one of 15 that started in 2013, is one of 44 in phase 3, and was the 116th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →29 of the 249 studies testing lenalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
University of Leeds · Sites in United Kingdom
Ages 18+
Eden Biltibo · Sites in United States
Ages 18–70
AbbVie · Sites in United States, France, Japan and 1 more country
Ages 18+
Dickran Kazandjian, MD · Sites in United States
University of Miami · Sites in United States
Ages 18+
By country, each count listing its studies:
Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
249 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 67 · Phase 2 164 · Phase 3 47 · Phase 4 10
First in 2002; this study’s year is marked. 15 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 249 interventional studies. Of the 155 that completed or were terminated, 81 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 249 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
149 studies in Multiple Myeloma by Bristol-Myers Squibb: 9 open now, 18 under way, 6 of them phase 3. Of 120 finished, 43 (36%) have results posted.
Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 89th largest by enrollment of the 108 interventional ones that give a count, is one of 8 that started in 2013, is one of 30 in phase 3, and was the 57th registered.
Bristol-Myers Squibb’s Multiple Myeloma studies by the year they started, since 2001.
14 of the studies testing lenalidomide in Multiple Myeloma that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01863550Phase 3ECOG-ACRIN Cancer Research GroupBortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | 2026-12-31 |
| NCT05665140Phase 3University Hopsital Schleswig Holstein Campus LübeckExpression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | 2027-08 |
| NCT02659293Phase 3University of ChicagoTrial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | 2027-11 |
| NCT04009109Alliance Foundation Trials, LLC.Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | 2026-12 |
| NCT03829371University of Turin, ItalySTUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | 2027-01-03 |
Add all 14 to your calendar (.ics) → With an account.
Among the 249 studies testing lenalidomide in Multiple Myeloma, from their registry updates:
Among Bristol-Myers Squibb’s 149 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to look at subjects who receive Lenalidomide, Dexamethasone, and Elotuzumab and determine if they will have lower surface CS1 expression on malignant plasma cells at the time of progression than those who receive Lenalidomide and Dexamethasone without Elotuzumab
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Inclusion Criteria:
Subjects who are newly diagnosed with symptomatic MM and who:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lenalidomide 25 mg capsules by mouth once daily (on Days 1-21), repeat every 28 days until subject meets criteria for discontinuation of study drug Dexamethasone 40 mg tablets by mouth weekly (on Days 1, 8, 15, 22), repeat every 28 days until subject meets criteria for discontinuation of study drug
Drug: Lenalidomide · Drug: Dexamethasone
Lenalidomide 25 mg capsules by mouth once daily (Days 1-21) Dexamethasone 28 mg tablets by mouth once daily \[Days 1, 8, 15, 22 (cycles 1 \& 2); Days 1 \& 15(cycles 3-18); Day 1 (cycle 19 \& beyond)\] Dexamethasone 40 mg tablets by mouth once daily \[Days 8 \& 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 \& beyond)\] Dexamethasone 8 mg IV (intravenous) solution once daily \[Days 1, 8, 15, 22 (cycles 1 \& 2); Days 1 \& 15 (cycles 3-18); Day 1 (cycle 19 \& beyond)\] Elotuzumab 10 mg/kg IV solution weekly \[Days 1, 8, 15, 22 (cycles 1 \& 2); Days 1 \& 15 (cycles 3-18)\] Elotuzumab 20 mg/kg IV solution on Day 1 (cycle 19 \& beyond) Repeat above-mentioned dose cycles every 28 days until subject meets criteria for discontinuation of study drug
Drug: Lenalidomide · Drug: Dexamethasone · Biological: Elotuzumab
Also known as: Revlimid®
Also known as: Decadron®, Dexamethasone Intensol®, Dexpak®, Taperpak®
Also known as: BMS-901608
Change From Baseline to Progression of the Cell Surface Expression of CS1 From Bone Marrow-Derived Multiple Myeloma (MM) Cells
CS1 (CD2 subset-1, also known as CRACC, SLAMF7, CD319) expression levels in multiple myeloma cells were analyzed from bone-marrow aspirates collected at baseline and at time of progression through mean fluorescent intensity. The following conditions were considered to describe multiple myeloma cells expressing CS1 (CS1+/CD38++/CD138+/CD56+/CD19-/CD45DIM)
Time frame: From baseline (screening) to time of progression (up to approximately 54 months)
Percent of Bone Marrow-Derived Multiple Myeloma (MM) Cells Expressing Cell Surface CS1 at Time of Progression
CS1 (CD2 subset-1, also known as CRACC, SLAMF7, CD319) expression levels in multiple myeloma cells were analyzed from bone-marrow aspirates collected at time of progression. The following conditions were considered to describe multiple myeloma cells expressing CS1 (CS1+/CD38++/CD138+/CD56+/CD19-/CD45DIM)
Time frame: Time of progression (up to approximately 54 months from pre-treatment screening)
Levels of CS1 Soluble Form (sCS1) in Serum
Expression levels of the free form of soluble CS1 were analyzed at different timepoints from serum samples derived from peripheral blood collection
Time frame: At baseline (screening), during main study therapy (cycle 3 day 1, up to 64 days) and at time of progression (up to approximately 31 months)
Change From Baseline in the Levels of CS1 Soluble Form (sCS1) in Serum During Therapy and At Progression
Expression levels of the free form of soluble CS1 were analyzed at different timepoints from serum samples derived from peripheral blood collection
Time frame: From baseline (screening) to cycle 3 day 1 of the main study therapy (up to 64 days) and from baseline (screening) to time of progression (up to approximately 31 months)
Change From Baseline in the Number of Circulating Multiple Myeloma (MM) Cells
Circulating MM cells isolated from peripheral blood
Time frame: From baseline (screening) to cycle 3 day 1 of the main study therapy (up to 64 days) and from baseline (screening) to the time of progression (up to approximately 54 months)
Change From Baseline in Cell Surface CS1 Expression Levels in Circulating Multiple Myeloma (MM) Cells
Circulating MM cells isolated from peripheral blood
Time frame: From baseline (screening) to cycle 3 day 1 of the main study therapy (up to 64 days) and from baseline (screening) to the time of progression (up to approximately 54 months)
CS1 Expression Levels in Matched Samples of Bone Marrow-Derived Multiple Myeloma (MM) Cells and Circulating MM Cells
CS1 expression levels analyzed from matching bone marrow aspirates (for bone marrow-derived MM cells) and from peripheral blood (for circulating tumor cells) collected from the same participants
Time frame: At baseline (screening), during main study therapy (cycle 3 day 1) and at time of progression (up to approximately 54 months)
| Milestone | E-Ld Cohort | Ld Cohort |
|---|---|---|
| Started | 13 | 10 |
| Completed | 3 | 0 |
| Not completed | 10 | 10 |
| Withdrew: Adverse event unrelated to study drug | 2 | 5 |
| Withdrew: Disease progression | 4 | 3 |
| Withdrew: Study drug toxicity | 3 | 0 |
| Withdrew: Maximum clinical benefit | 0 | 1 |
| Withdrew: Poor/non-compliance | 0 | 1 |
| Withdrew: Participant request to discontinue | 1 | 0 |
CS1 (CD2 subset-1, also known as CRACC, SLAMF7, CD319) expression levels in multiple myeloma cells were analyzed from bone-marrow aspirates collected at baseline and at time of progression through mean fluorescent intensity. The following conditions were considered to describe multiple myeloma cells expressing CS1 (CS1+/CD38++/CD138+/CD56+/CD19-/CD45DIM)
No measurements were reported for this outcome.
CS1 (CD2 subset-1, also known as CRACC, SLAMF7, CD319) expression levels in multiple myeloma cells were analyzed from bone-marrow aspirates collected at time of progression. The following conditions were considered to describe multiple myeloma cells expressing CS1 (CS1+/CD38++/CD138+/CD56+/CD19-/CD45DIM)
| Percent of cells expressing CS1 | E-Ld Cohort | Ld Cohort |
|---|---|---|
| Percent of Bone Marrow-Derived Multiple Myeloma (MM) Cells Expressing Cell Surface CS1 at Time of Progression | 46.59 (0.0 to 99.1) | 84.62 (NA to NA) |
Expression levels of the free form of soluble CS1 were analyzed at different timepoints from serum samples derived from peripheral blood collection
| ug/L | E-Ld Cohort | Ld Cohort |
|---|---|---|
| Baseline | 3.60 (0.7 to 7.4) | 13.27 (2.2 to 79.8) |
| Cycle 3 day 1 of main study therapy | 0.15 (0.1 to 0.3) | 0.72 (0.2 to 3.0) |
| Time of progression | 0.39 (0.2 to 0.5) | 49.85 (NA to NA) |
Expression levels of the free form of soluble CS1 were analyzed at different timepoints from serum samples derived from peripheral blood collection
| ug/L | E-Ld Cohort | Ld Cohort |
|---|---|---|
| From baseline to Cycle 3 day 1 of main study therapy | -3.51 (-6.9 to -0.6) | -4.08 (-15.1 to -1.6) |
| From baseline to time of progression | -0.85 (-6.9 to -0.4) | -17.41 (NA to NA) |
Circulating MM cells isolated from peripheral blood
No measurements were reported for this outcome.
Circulating MM cells isolated from peripheral blood
No measurements were reported for this outcome.
CS1 expression levels analyzed from matching bone marrow aspirates (for bone marrow-derived MM cells) and from peripheral blood (for circulating tumor cells) collected from the same participants
No measurements were reported for this outcome.
Collected over From first dose to 60 days following last dose (up to approximately 80 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| E-Ld Cohort | 8/13 (61.5%) | 9/13 (69.2%) | 13/13 (100%) |
| Ld Cohort | 5/10 (50%) | 7/10 (70%) | 10/10 (100%) |
| Event | E-Ld Cohort | Ld Cohort |
|---|---|---|
| PneumoniaInfections and infestations | 1/13 | 2/10 |
| Femur fractureInjury, poisoning and procedural complications | 0/13 | 2/10 |
| AnaemiaBlood and lymphatic system disorders | 1/13 | 1/10 |
| Sinus tachycardiaCardiac disorders | 0/13 | 1/10 |
| CataractEye disorders | 1/13 | 1/10 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/13 | 1/10 |
| BronchitisInfections and infestations | 1/13 | 1/10 |
| Electrolyte imbalanceMetabolism and nutrition disorders | 0/13 | 1/10 |
| Acute lymphocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/13 | 1/10 |
| Transient ischaemic attackNervous system disorders | 0/13 | 1/10 |
| Event | E-Ld Cohort | Ld Cohort |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 3/13 | 6/10 |
| DiarrhoeaGastrointestinal disorders | 5/13 | 6/10 |
| Oedema peripheralGeneral disorders | 2/13 | 5/10 |
| FatigueGeneral disorders | 6/13 | 2/10 |
| Back painMusculoskeletal and connective tissue disorders | 2/13 | 4/10 |
| ConstipationGastrointestinal disorders | 4/13 | 3/10 |
| RashSkin and subcutaneous tissue disorders | 4/13 | 1/10 |
| NauseaGastrointestinal disorders | 2/13 | 3/10 |
| PyrexiaGeneral disorders | 1/13 | 3/10 |
| HypokalaemiaMetabolism and nutrition disorders | 1/13 | 3/10 |
| Age, Continuous(Years) | E-Ld Cohort | Ld Cohort | Total |
|---|---|---|---|
| Mean | 74.8 ± 6.77 | 71.3 ± 6.53 | 73.3 ± 6.75 |
| Sex: Female, Male(Participants) | E-Ld Cohort | Ld Cohort | Total |
|---|---|---|---|
| Female | 6 | 6 | 12 |
| Male | 7 | 4 | 11 |
| Ethnicity (NIH/OMB)(Participants) | E-Ld Cohort | Ld Cohort | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 2 | 3 | 5 |
| Unknown or Not Reported | 11 | 7 | 18 |
| Race (NIH/OMB)(Participants) | E-Ld Cohort | Ld Cohort | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 12 | 9 | 21 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2013 to primary completion in Jun 2020, 80 months.
Results were first posted in Jul 2021, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lenalidomide · Dexamethasone